Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- -
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1346
- Registration Number
- NCT02294058
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Neurological Research Institute Inc, Columbus, Ohio, United States
🇺🇸The Polyclinic, Seattle, Washington, United States
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1320
- Registration Number
- NCT02047734
- Locations
- 🇺🇸
Neurostudies Inc, Port Charlotte, Florida, United States
🇵🇱RESMEDICA Spolka z o.o., Kielce, Poland
🇵🇱Receptos Study Site 402, Olsztyn, Poland
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 245
- Registration Number
- NCT01892722
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Avonex®: Safety, Blood Levels and Effects
- Conditions
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Trio Medicines Ltd.
- Target Recruit Count
- 77
- Registration Number
- NCT01863069
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Biocad
- Target Recruit Count
- 32
- Registration Number
- NCT01766024
- Locations
- 🇷🇺
City Mariin Hospital, St. Petersburg, Russian Federation
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Revalesio Corporation
- Registration Number
- NCT01714089
- Locations
- 🇺🇸
Mt. Sinai School of Medicine, New York, New York, United States
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 835
- Registration Number
- NCT01412333
- Locations
- 🇺🇸
Infinity Clinical Research, Hollywood, Florida, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Advanced Neurosciences Research LLC, Fort Collins, Colorado, United States
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
- Conditions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 100
- Registration Number
- NCT01272128
- Locations
- 🇧🇪
Research Site, Liège, Belgium
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 821
- Registration Number
- NCT01247324
- Locations
- 🇺🇸
Northwestern University; Dept. of Neurology, Chicago, Illinois, United States
🇺🇸The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸Uni of Vermont Medical Center;, Burlington, Vermont, United States
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
- Conditions
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 79
- Registration Number
- NCT01201343
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.